| Biallelic variants in NOS3 and GUCY1A3, the two major genes of the nitric oxide pathway, cause moyamoya cerebral angiopathy. | Biallelic variants in NOS3 and GUCY1A3, the two major genes of the nitric oxide pathway, cause moyamoya cerebral angiopathy.
Guey S, Hervé D, Kossorotoff M, Ha G, Aloui C, Bergametti F, Arnould M, Guenou H, Hadjadj J, Dubois Teklali F, Riant F, Balligand JL, Uzan G, Villoutreix BO, Tournier-Lasserve E., Free PMC Article | 03/29/2023 |
| Activation mechanism of human soluble guanylate cyclase by stimulators and activators. | Activation mechanism of human soluble guanylate cyclase by stimulators and activators.
Liu R, Kang Y, Chen L., Free PMC Article | 10/16/2021 |
| Higher susceptibility to heme oxidation and lower protein stability of the rare alpha1C517Ybeta1 sGC variant associated with moyamoya syndrome. | Higher susceptibility to heme oxidation and lower protein stability of the rare α(1)C517Yβ(1) sGC variant associated with moyamoya syndrome.
Sharina I, Lezgyieva K, Krutsenko Y, Martin E., Free PMC Article | 09/18/2021 |
| Inflammation in the Human Periodontium Induces Downregulation of the alpha1- and beta1-Subunits of the sGC in Cementoclasts. | Inflammation in the Human Periodontium Induces Downregulation of the α(1)- and β(1)-Subunits of the sGC in Cementoclasts.
Korkmaz Y, Puladi B, Galler K, Kämmerer PW, Schröder A, Gölz L, Sparwasser T, Bloch W, Friebe A, Deschner J., Free PMC Article | 04/3/2021 |
| Soluble guanylyl cyclase alpha1 subunit is a key mediator of proliferation, survival, and migration in ECC-1 and HeLa cell lines. | Soluble guanylyl cyclase α1 subunit is a key mediator of proliferation, survival, and migration in ECC-1 and HeLa cell lines.
Ronchetti SA, Pino MTL, Cordeiro G, Bollani SN, Ricci AG, Duvilanski BH, Cabilla JP., Free PMC Article | 11/21/2020 |
| Genetic variation at the coronary artery disease risk locus GUCY1A3 modifies cardiovascular disease prevention effects of aspirin. | Genetic variation at the coronary artery disease risk locus GUCY1A3 modifies cardiovascular disease prevention effects of aspirin.
Hall KT, Kessler T, Buring JE, Passow D, Sesso HD, Zee RYL, Ridker PM, Chasman DI, Schunkert H., Free PMC Article | 10/24/2020 |
| Results suggest mechanistic insights into the molecular pathway for soluble guanylyl cyclase (sGC) activation. | Synergistic mutations in soluble guanylyl cyclase (sGC) reveal a key role for interfacial regions in the sGC activation mechanism.
Childers KC, Yao XQ, Giannakoulias S, Amason J, Hamelberg D, Garcin ED., Free PMC Article | 06/27/2020 |
| Homozygous GUCY1A3 risk allele carriers are at increased risk of cardiovascular death or stent thrombosis within 30 days after coronary stenting, likely due to higher on-aspirin platelet reactivity. | Association of the coronary artery disease risk gene GUCY1A3 with ischaemic events after coronary intervention.
Kessler T, Wolf B, Eriksson N, Kofink D, Mahmoodi BK, Rai H, Tragante V, Åkerblom A, Becker RC, Bernlochner I, Bopp R, James S, Katus HA, Mayer K, Munz M, Nordio F, O'Donoghue ML, Sager HB, Sibbing D, Solakov L, Storey RF, Wobst J, Asselbergs FW, Byrne RA, Erdmann J, Koenig W, Laugwitz KL, Ten Berg JM, Wallentin L, Kastrati A, Schunkert H. | 06/27/2020 |
| Our results indicate that the GUCY1A3 rs1842896 polymorphism is an large artery atherosclerotic (LAA) stroke risk factor in Southern Han Chinese. | Associations between GUCY1A3 genetic polymorphisms and large artery atherosclerotic stroke risk in Chinese Han population: a case-control study.
Li JL, Liu LY, Jiang DD, Jiang YY, Zhou GQ, Mo DC, Luo M., Free PMC Article | 06/6/2020 |
| Genetic predisposition to enhanced nitric oxide signaling was associated with reduced blood pressure, improved renal and pulmonary function, and significantly reduced risks of coronary heart disease in people with rs7692387 GUCY1A3 variant. | Phenotypic Consequences of a Genetic Predisposition to Enhanced Nitric Oxide Signaling.
Emdin CA, Khera AV, Klarin D, Natarajan P, Zekavat SM, Nomura A, Haas M, Aragam K, Ardissino D, Wilson JG, Schunkert H, McPherson R, Watkins H, Elosua R, Bown MJ, Samani NJ, Baber U, Erdmann J, Gormley P, Palotie A, Stitziel NO, Gupta N, Danesh J, Saleheen D, Gabriel S, Kathiresan S., Free PMC Article | 04/13/2019 |
| data have provided some evidence for an alteration in the expression of alpha1 and beta1 oluble guanylyl cyclase alternative splicing forms which may contribute to the loss of sGC functions in breast cancer | Differential expression of alternative transcripts of soluble guanylyl cyclase, GYCY1a3 and GUCY1b3 genes, in the malignant and benign breast tumors.
Mohammadoo Khorasani M, Karami Tehrani F, Parizadeh SMR, Atri M. | 03/16/2019 |
| GCAP1 and GCAP2 bound to different regions on the target guanylate cyclase type 1 with submicromolar affinity (apparent KD-values of 663 +/- 121 nM and 231 +/- 63 nM for Ca(2+)-free GCAP1 and GCAP2, respectively). | Label-free quantification of calcium-sensor targeting to photoreceptor guanylate cyclase and rhodopsin kinase by backscattering interferometry.
Sulmann S, Kussrow A, Bornhop DJ, Koch KW., Free PMC Article | 11/10/2018 |
| Human Red Blood Cells carry catalytically active alpha1beta1-soluble guanylate cyclase (isoform 1). Red cell soluble guanylate cyclase activity is fully preserved in patients with stable coronary artery disease. | Identification of a soluble guanylate cyclase in RBCs: preserved activity in patients with coronary artery disease.
Cortese-Krott MM, Mergia E, Kramer CM, Lückstädt W, Yang J, Wolff G, Panknin C, Bracht T, Sitek B, Pernow J, Stasch JP, Feelisch M, Koesling D, Kelm M., Free PMC Article | 07/14/2018 |
| Peptide B-8R killed both androgen-dependent and androgen-independent prostate cancer cells that expressed sGCalpha1, but not cells that do not express this gene. Peptide B-8R induced apoptosis of prostate cancer cells. | Peptide B targets soluble guanylyl cyclase α1 and kills prostate cancer cells.
Zhou J, Gao S, Hsieh CL, Malla M, Shemshedini L., Free PMC Article | 10/14/2017 |
| In conclusion, rare coding variants in GUCY1A3 lead to reduced cGMP formation which can be rescued by a soluble guanylyl cyclase stimulator in vitro | Stimulators of the soluble guanylyl cyclase: promising functional insights from rare coding atherosclerosis-related GUCY1A3 variants.
Wobst J, von Ameln S, Wolf B, Wierer M, Dang TA, Sager HB, Tennstedt S, Hengstenberg C, Koesling D, Friebe A, Braun SL, Erdmann J, Schunkert H, Kessler T. | 09/30/2017 |
| Rs7692387 is located in an intronic site that modulates GUCY1A3 promoter activity. The transcription factor ZEB1 binds preferentially to the nonrisk allele, leading to an increase in GUCY1A3 expression, higher sGC levels, and higher sGC activity after stimulation. | Functional Characterization of the GUCY1A3 Coronary Artery Disease Risk Locus.
Kessler T, Wobst J, Wolf B, Eckhold J, Vilne B, Hollstein R, von Ameln S, Dang TA, Sager HB, Moritz Rumpf P, Aherrahrou R, Kastrati A, Björkegren JLM, Erdmann J, Lusis AJ, Civelek M, Kaiser FJ, Schunkert H., Free PMC Article | 08/19/2017 |
| Mutations in the GUCY1A3 gene are associated with moyamoya disease, achalasia, and hypertension. | Disrupted nitric oxide signaling due to GUCY1A3 mutations increases risk for moyamoya disease, achalasia and hypertension.
Wallace S, Guo DC, Regalado E, Mellor-Crummey L, Bamshad M, Nickerson DA, Dauser R, Hanchard N, Marom R, Martin E, Berka V, Sharina I, Ganesan V, Saunders D, Morris SA, Milewicz DM., Free PMC Article | 07/29/2017 |
| Expression of the alpha1-A680T sGC variant in reporter cells resulted in higher cyclic guanosine monophosphate production compared with the wild-type enzyme and the purified alpha1-A680T sGC exhibited enhanced sensitivity to nitric oxide in vitro. | α1-A680T variant in GUCY1A3 as a candidate conferring protection from pulmonary hypertension among Kyrgyz highlanders.
Wilkins MR, Aldashev AA, Wharton J, Rhodes CJ, Vandrovcova J, Kasperaviciute D, Bhosle SG, Mueller M, Geschka S, Rison S, Kojonazarov B, Morrell NW, Neidhardt I, Surmeli NB, Aitman TJ, Stasch JP, Behrends S, Marletta MA. | 07/25/2015 |
| Dynamic interplay between hsp90, apo-sGC-beta1, and sGC-alpha1 in response to NO is unprecedented and represent new steps by which cells can modulate the heme content and activity of sGC for signaling cascades. | Nitric oxide and heat shock protein 90 activate soluble guanylate cyclase by driving rapid change in its subunit interactions and heme content.
Ghosh A, Stasch JP, Papapetropoulos A, Stuehr DJ., Free PMC Article | 10/11/2014 |
| ZNF280B upregulates GUCY1A3 expression and downregulates TP53 in prostate cancer cells. | Zinc Finger 280B regulates sGCα1 and p53 in prostate cancer cells.
Gao S, Hsieh CL, Zhou J, Shemshedini L., Free PMC Article | 09/6/2014 |
| homozygous mutations in GUCY1A3, which encodes the alpha1 subunit of soluble guanylate cyclase, the major receptor for nitric oxide, might play a role in moyamoya and achalasia | Loss of α1β1 soluble guanylate cyclase, the major nitric oxide receptor, leads to moyamoya and achalasia.
Hervé D, Philippi A, Belbouab R, Zerah M, Chabrier S, Collardeau-Frachon S, Bergametti F, Essongue A, Berrou E, Krivosic V, Sainte-Rose C, Houdart E, Adam F, Billiemaz K, Lebret M, Roman S, Passemard S, Boulday G, Delaforge A, Guey S, Dray X, Chabriat H, Brouckaert P, Bryckaert M, Tournier-Lasserve E., Free PMC Article | 05/3/2014 |
| The G-protein regulator LGN modulates the activity of the NO receptor soluble guanylate cyclase | The G-protein regulator LGN modulates the activity of the NO receptor soluble guanylate cyclase.
Chauhan S, Jelen F, Sharina I, Martin E., Free PMC Article | 11/17/2012 |
| GCS-alpha-1 regulation of p53 activity is important in prostate cancer biology and may represent an important mechanism of p53 down-regulation. | Soluble guanylyl cyclase α1 and p53 cytoplasmic sequestration and down-regulation in prostate cancer.
Cai C, Hsieh CL, Gao S, Kannan A, Bhansali M, Govardhan K, Dutta R, Shemshedini L., Free PMC Article | 05/26/2012 |
| We concluded that the alpha-subunit and the beta(1)(191-619) domain exert structural strains on the heme domain. | Quaternary structure controls ligand dynamics in soluble guanylate cyclase.
Yoo BK, Lamarre I, Martin JL, Negrerie M., Free PMC Article | 04/28/2012 |
| analysis of pharmacological response to direct sGC activators in coronary artery disease patients | Measuring oxidative burden and predicting pharmacological response in coronary artery disease patients with a novel direct activator of haem-free/oxidised sGC.
Ahrens I, Habersberger J, Baumlin N, Qian H, Smith BK, Stasch JP, Bode C, Schmidt HH, Peter K. | 04/14/2012 |